Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M40403 + opioid refers to the combination of **M40403**, a synthetic manganese-containing superoxide dismutase (SOD) mimetic, with an **opioid analgesic**. M40403 selectively removes superoxide anion and has been investigated as an anti-inflammatory and potentially for pain management. Opioids are a class of analgesics that act as agonists at opioid receptors (mainly the mu opioid receptor), providing relief for moderate to severe pain. This combination is theoretical or investigational; there are no known marketed products or late-stage clinical trials specifically combining M40403 with an opioid. However, the concept fits with the ongoing research into multimodal analgesia, where opioid analgesics are paired with agents targeting oxidative stress or inflammation to provide synergistic pain control or reduce opioid requirements[3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on M40403 + opioid.